Molecular mechanisms of action of ribavirin

Jean L. Patterson, Roberto Fernandez-Larsson

    Research output: Contribution to journalArticlepeer-review

    226 Scopus citations


    Ribavirin (l-β-d-ribofuranosyl-l,2,4-triazole-3-carboxamide) is a broad-spectrum antiviral agent whose molecular mode of action remains remarkably controversial. This antiviral agent was approved by the U.S. Food and Drug Administration in 1986 for use as an aerosol for infants with serious infections due to respiratory syncytial virus. Ribavirin is and has been under clinical investigation for activity against a variety of viral illnesses, including those due to influenza virus, Lassa fever virus, Hantaan virus, and human immunodeficiency virus (HIV). There has been a great deal of clinical interest in the utilization of ribavirin for treatment of infections due to HIV. It has been reported to slow the development of AIDS in HIV-infected patients. We describe here the major mechanisms of action of this newly licensed antiviral agent.

    Original languageEnglish (US)
    Pages (from-to)1139-1146
    Number of pages8
    JournalReviews of Infectious Diseases
    Issue number6
    StatePublished - Nov 1990

    ASJC Scopus subject areas

    • Microbiology (medical)


    Dive into the research topics of 'Molecular mechanisms of action of ribavirin'. Together they form a unique fingerprint.

    Cite this